Company · CIK 0001567514 · SIC 2834 — Pharmaceutical Preparations
Intra-Cellular Therapies, Inc. · ITCI
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2016 SForm 4 → | Dec 19, 5:50 pm EST | Kimberly E. VanoverSVP, Clinical Development | 9,375 | $15.23 | $142,773 | 9,375 | −50.0% | plan? |
| Dec 15, 2016 MForm 4 → | Dec 19, 5:50 pm EST | Kimberly E. VanoverSVP, Clinical Development | 18,750 | $1.46 | $27,425 | 11,250 | — | plan? |
| Dec 6, 2016 PForm 4 → | Dec 7, 4:35 pm EST | Moshe Alafi10% Owner | 65,000 | $16.27 | $1,057,483 | 3,695,205 | +1.79% | plan? |
| Dec 6, 2016 PForm 4 → | Dec 7, 4:32 pm EST | Christopher D AlafiDirector, 10% Owner | 65,000 | $16.27 | $1,057,483 | 3,695,205 | +1.79% | plan? |
| Dec 6, 2016 PForm 4 → | Dec 7, 4:21 pm EST | ALAFI CAPITAL CO LLC10% Owner | 65,000 | $16.27 | $1,057,483 | 3,695,205 | +1.79% | plan? |
| Dec 4, 2016 MForm 4 → | Jan 5, 2017, 5:47 pm EST | Robert E DavisSVP, Chief Scientific Officer | 1,757 | — | — | 26,757 | — | plan? late |
| Nov 14, 2016 PForm 4 → | Nov 17, 4:35 pm EST | Moshe Alafi10% Owner | 34,000 | $14.50 | $492,969 | 3,630,205 | +0.95% | plan? late |
| Nov 14, 2016 PForm 4 → | Nov 17, 4:34 pm EST | ALAFI CAPITAL CO LLC10% Owner | 34,000 | $14.50 | $492,969 | 3,630,205 | +0.95% | plan? late |
| Nov 14, 2016 PForm 4 → | Nov 17, 4:32 pm EST | Christopher D AlafiDirector, 10% Owner | 34,000 | $14.50 | $492,969 | 3,630,205 | +0.95% | plan? late |
| Sep 30, 2016 AForm 4 → | Oct 4, 4:45 pm EDT | Robert L Van NostrandDirector | 328 | — | — | 1,955 | — | plan? |
| Sep 30, 2016 AForm 4 → | Oct 4, 4:44 pm EDT | Rory B RiggsDirector | 951 | — | — | 31,670 | — | plan? |
| Sep 30, 2016 AForm 4 → | Oct 4, 4:43 pm EDT | Richard A LernerDirector | 902 | — | — | 4,886 | — | plan? |
| Sep 30, 2016 AForm 4 → | Oct 4, 4:42 pm EDT | Christopher D AlafiDirector, 10% Owner | 951 | — | — | 730,529 | — | plan? |
| Sep 30, 2016 AForm 4 → | Oct 4, 4:40 pm EDT | Joel S MarcusDirector | 984 | — | — | 20,677 | — | plan? |
| Jun 30, 2016 AForm 4 → | Jul 5, 4:46 pm EDT | Christopher D AlafiDirector, 10% Owner | 373 | — | — | 729,578 | — | plan? |
| Jun 30, 2016 AForm 4 → | Jul 5, 4:44 pm EDT | Richard A LernerDirector | 354 | — | — | 3,984 | — | plan? |
| Jun 30, 2016 AForm 4 → | Jul 5, 4:42 pm EDT | Robert L Van NostrandDirector | 128 | — | — | 1,627 | — | plan? |
| Jun 30, 2016 AForm 4 → | Jul 5, 4:40 pm EDT | Rory B RiggsDirector | 373 | — | — | 30,719 | — | plan? |
| Jun 30, 2016 AForm 4 → | Jul 5, 4:38 pm EDT | Joel S MarcusDirector | 386 | — | — | 19,693 | — | plan? |
| Mar 31, 2016 AForm 4 → | Apr 4, 4:59 pm EDT | Robert L Van NostrandDirector | 134 | — | — | 1,499 | — | plan? |
| Mar 31, 2016 AForm 4 → | Apr 4, 4:58 pm EDT | Rory B RiggsDirector | 382 | — | — | 16,061 | — | plan? |
| Mar 31, 2016 AForm 4 → | Apr 4, 4:53 pm EDT | Joel S MarcusDirector | 386 | — | — | 19,307 | — | plan? |
| Mar 31, 2016 AForm 4 → | Apr 4, 4:50 pm EDT | Richard A LernerDirector | 364 | — | — | 3,630 | — | plan? |
| Mar 31, 2016 AForm 4 → | Apr 4, 4:48 pm EDT | Christopher D AlafiDirector, 10% Owner | 377 | — | — | 729,205 | — | plan? |
| Feb 29, 2016 PForm 4 → | Feb 29, 5:32 pm EST | Christopher D AlafiDirector, 10% Owner | 100,000 | $29.70 | $2,970,300 | 728,828 | +15.9% | plan? |
| Feb 18, 2016 MForm 4 → | Feb 19, 4:25 pm EST | Richard A LernerDirector | 10,000 | $1.36 | $13,600 | 47,500 | — | plan? |
| Dec 31, 2015 AForm 4 → | Jan 5, 2016, 7:09 pm EST | Robert L Van NostrandDirector | 69 | $53.79 | $3,712 | 1,365 | — | plan? |
| Dec 31, 2015 AForm 4 → | Jan 5, 2016, 5:13 pm EST | Rory B RiggsDirector | 197 | $53.79 | $10,597 | 15,679 | — | plan? |
| Dec 31, 2015 AForm 4 → | Jan 5, 2016, 5:11 pm EST | Joel S MarcusDirector | 199 | $53.79 | $10,704 | 18,921 | — | plan? |
| Dec 31, 2015 AForm 4 → | Jan 5, 2016, 5:00 pm EST | Christopher D AlafiDirector, 10% Owner | 195 | $53.79 | $10,489 | 628,828 | — | plan? |
| Dec 31, 2015 AForm 4 → | Jan 5, 2016, 4:59 pm EST | Richard A LernerDirector | 188 | $53.79 | $10,113 | 3,266 | — | plan? |
| Dec 14, 2015 SForm 4 → | Dec 15, 8:25 pm EST | Lawrence J. HinelineVP of Finance CFO | 45,000 | $51.45 | $2,315,366 | 52,200 | −46.3% | plan? |
| Dec 11, 2015 SForm 4 → | Dec 15, 8:27 pm EST | Sharon MatesChairman, President & CEO, Director | 51,500 | $53.87 | $2,774,441 | 1,086,185 | −4.53% | plan? |
| Dec 11, 2015 MForm 4 → | Dec 15, 8:27 pm EST | Sharon MatesChairman, President & CEO, Director | 68,750 | $1.12 | $77,125 | 1,137,685 | — | plan? |
| Dec 4, 2015 SForm 4 → | Dec 8, 5:30 pm EST | Joel S MarcusDirector | 92,700 | $54.47 | $5,049,388 | 1,191,156 | −7.22% | plan? |
| Nov 24, 2015 MForm 4 → | Dec 15, 8:25 pm EST | Lawrence J. HinelineVP of Finance CFO | 47,500 | $1.23 | $58,250 | 62,200 | — | plan? late |
| Nov 24, 2015 SForm 4 → | Nov 27, 8:29 am EST | Lawrence J. HinelineVP of Finance CFO | 5,000 | $55.00 | $275,000 | 59,700 | −7.73% | plan? |
| Sep 30, 2015 AForm 4 → | Oct 2, 5:42 pm EDT | Christopher D AlafiDirector, 10% Owner | 262 | — | — | 628,633 | — | plan? |
| Sep 30, 2015 AForm 4 → | Oct 2, 5:40 pm EDT | Richard A LernerDirector | 252 | — | — | 3,078 | — | plan? |
| Sep 30, 2015 AForm 4 → | Oct 2, 5:38 pm EDT | Joel S MarcusDirector | 268 | — | — | 18,722 | — | plan? |
| Sep 30, 2015 AForm 4 → | Oct 2, 5:37 pm EDT | Rory B RiggsDirector | 265 | — | — | 15,482 | — | plan? |
| Sep 30, 2015 AForm 4 → | Oct 2, 5:35 pm EDT | Robert L Van NostrandDirector | 93 | — | — | 1,296 | — | plan? |
| Sep 9, 2015 MForm 4 → | Sep 11, 4:53 pm EDT | Allen A. FienbergVP of Business Development | 12,500 | $1.36 | $17,000 | 295,000 | — | plan? |
| Aug 19, 2015 SForm 4 → | Sep 11, 4:53 pm EDT | Allen A. FienbergVP of Business Development | 10,200 | $30.30 | $309,060 | 197,823 | −4.90% | plan? late |
| Jun 30, 2015 AForm 4 → | Jul 2, 4:48 pm EDT | Robert L Van NostrandDirector | 117 | — | — | 1,203 | — | plan? |
| Jun 30, 2015 AForm 4 → | Jul 2, 4:47 pm EDT | Rory B RiggsDirector | 332 | — | — | 15,217 | — | plan? |
| Jun 30, 2015 AForm 4 → | Jul 2, 4:46 pm EDT | Joel S MarcusDirector | 336 | — | — | 18,454 | — | plan? |
| Jun 30, 2015 AForm 4 → | Jul 2, 4:46 pm EDT | Richard A LernerDirector | 316 | — | — | 2,826 | — | plan? |
| Jun 30, 2015 AForm 4 → | Jul 2, 4:45 pm EDT | Christopher D AlafiDirector, 10% Owner | 328 | — | — | 628,371 | — | plan? |
| Jun 8, 2015 SForm 4 → | Jun 9, 5:04 pm EDT | Lawrence P. WennogleVice President, Drug Discovery | 25,000 | $26.84 | $671,000 | 126,500 | −16.5% | plan? |
| May 19, 2015 MForm 4 → | May 20, 5:19 pm EDT | Lawrence P. WennogleVice President, Drug Discovery | 47,500 | $1.23 | $58,250 | 151,500 | — | plan? |
| Mar 31, 2015 AForm 4 → | Apr 2, 4:59 pm EDT | Rory B RiggsDirector | 444 | — | — | 14,885 | — | plan? |
| Mar 31, 2015 MForm 4 → | Apr 2, 4:59 pm EDT | Allen A. FienbergVP of Business Development | 12,500 | $0.60 | $7,500 | 282,500 | — | plan? |
| Mar 31, 2015 AForm 4 → | Apr 2, 4:59 pm EDT | Robert L Van NostrandDirector | 157 | — | — | 1,086 | — | plan? |
| Mar 31, 2015 AMForm 4 → | Apr 2, 4:58 pm EDT | Joel S MarcusDirector | 15,450 | $1.23 | $18,400 | 18,118 | — | plan? |
| Mar 31, 2015 AForm 4 → | Apr 2, 4:58 pm EDT | Richard A LernerDirector | 423 | — | — | 2,510 | — | plan? |
| Mar 31, 2015 AForm 4 → | Apr 2, 4:58 pm EDT | Christopher D AlafiDirector, 10% Owner | 439 | — | — | 628,043 | — | plan? |
| Mar 11, 2015 PForm 4 → | Mar 12, 6:24 pm EDT | Christopher D AlafiDirector, 10% Owner | 625,000 | $24.00 | $15,000,000 | 627,604 | +24,002% | plan? |
| Mar 11, 2015 PForm 4 → | Mar 12, 1:04 pm EDT | Morton I. Sosland10% Owner | 250,000 | $24.00 | $6,000,000 | 2,198,554 | +12.8% | plan? |
| Jan 14, 2015 SForm 4 → | Jan 16, 4:31 pm EST | Allen A. FienbergVP of Business Development | 5,000 | $19.00 | $95,000 | 270,000 | −1.82% | plan? |
| Dec 31, 2014 AForm 4 → | Jan 5, 2015, 5:35 pm EST | Robert L Van NostrandDirector | 212 | — | — | 929 | — | plan? |
| Dec 31, 2014 AForm 4 → | Jan 5, 2015, 5:31 pm EST | Rory B RiggsDirector | 601 | — | — | 14,441 | — | plan? |
| Dec 31, 2014 AForm 4 → | Jan 5, 2015, 5:28 pm EST | Joel S MarcusDirector | 609 | — | — | 2,668 | — | plan? |
| Dec 31, 2014 AForm 4 → | Jan 5, 2015, 5:21 pm EST | Richard A LernerDirector | 508 | — | — | 2,087 | — | plan? |
| Dec 31, 2014 AForm 4 → | Jan 5, 2015, 5:18 pm EST | Christopher D AlafiDirector, 10% Owner | 594 | — | — | 2,604 | — | plan? |
| Feb 5, 2014 PForm 4/A → | Apr 20, 2016, 4:30 pm EDT | Rory B RiggsDirector | 28,571 | $17.50 | $499,993 | 26,091 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2019 MForm 4 → | Mar 1, 7:41 pm EST | Lawrence J. HinelineSVP of Finance CFO | 10,400 | — | — | 9,600 | — | |
| Jan 8, 2019 AForm 4 → | Jan 10, 4:28 pm EST | Andrew SatlinEVP and Chief Medical Officer | 163,178 | — | — | 68,735 | — | |
| Jan 8, 2019 AForm 4 → | Jan 10, 4:18 pm EST | Mark NeumannEVP, Chief Commercial Officer | 149,191 | — | — | 62,843 | — | |
| Jan 8, 2019 AForm 4 → | Jan 8, 9:16 pm EST | Robert E DavisSVP, Chief Scientific Officer | 130,542 | — | — | 54,988 | — | |
| Jan 4, 2019 AMForm 4 → | Jan 8, 9:28 pm EST | Sharon MatesChairman, President & CEO, Director | 304,988 | — | — | 125,687 | — | |
| Jan 4, 2019 AMForm 4 → | Jan 8, 9:24 pm EST | Michael HalsteadEVP and General Counsel | 142,974 | — | — | 58,915 | — | |
| Jan 4, 2019 AMForm 4 → | Jan 8, 9:21 pm EST | Lawrence J. HinelineSVP of Finance CFO | 142,974 | — | — | 58,915 | — | |
| Jan 4, 2019 AMForm 4 → | Jan 8, 9:19 pm EST | Kimberly E. VanoverSVP, Early Stage Clinical Dev. | 141,420 | — | — | 58,915 | — | |
| Jan 3, 2019 MForm 4 → | Jan 3, 9:02 pm EST | Sharon MatesChairman, President & CEO, Director | 45,598 | — | — | 68,681 | — | |
| Jan 3, 2019 MForm 4 → | Jan 3, 8:58 pm EST | Michael HalsteadEVP and General Counsel | 21,458 | — | — | 32,320 | — | |
| Jan 3, 2019 MForm 4 → | Jan 3, 8:46 pm EST | Kimberly E. VanoverSVP, Early Stage Clinical Dev. | 18,809 | — | — | 32,320 | — | |
| Jan 3, 2019 MForm 4 → | Jan 3, 8:42 pm EST | Robert E DavisSVP, Chief Scientific Officer | 18,809 | — | — | 32,320 | — | |
| Jan 3, 2019 MForm 4 → | Jan 3, 8:23 pm EST | Lawrence J. HinelineSVP of Finance CFO | 21,458 | — | — | 32,320 | — | |
| Dec 10, 2018 MForm 4 → | Dec 11, 5:55 pm EST | Sharon MatesChairman, President & CEO, Director | 50,000 | — | — | 0 | — | |
| Dec 4, 2018 MForm 4 → | Dec 7, 4:44 pm EST | Robert E DavisSVP, Chief Scientific Officer | 1,758 | — | — | 0 | — | |
| Oct 22, 2018 MForm 4 → | Oct 24, 4:33 pm EDT | Richard A LernerDirector | 12,500 | — | — | 0 | — | |
| Oct 15, 2018 AForm 4 → | Oct 17, 4:28 pm EDT | Mark NeumannEVP, Chief Commercial Officer | 95,644 | — | — | 40,344 | — | |
| Jun 18, 2018 AForm 4 → | Jun 20, 4:52 pm EDT | Rory B RiggsDirector | 14,189 | — | — | 14,189 | — | |
| Jun 18, 2018 AForm 4 → | Jun 20, 4:49 pm EDT | Joel S MarcusDirector | 14,189 | — | — | 14,189 | — | |
| Jun 18, 2018 AForm 4 → | Jun 20, 4:47 pm EDT | Robert L Van NostrandDirector | 20,000 | — | — | 20,000 | — | |
| Jun 18, 2018 AForm 4 → | Jun 20, 4:45 pm EDT | Richard A LernerDirector | 20,000 | — | — | 20,000 | — | |
| Jun 18, 2018 AForm 4 → | Jun 20, 4:40 pm EDT | Christopher D AlafiDirector | 20,000 | — | — | 20,000 | — | |
| Jan 3, 2018 AMForm 4 → | Jan 5, 8:19 pm EST | Sharon MatesChairman, President & CEO, Director | 259,355 | — | — | 103,021 | — | |
| Jan 3, 2018 AMForm 4 → | Jan 5, 8:14 pm EST | Kimberly E. VanoverSVP, Clinical Development | 117,846 | — | — | 48,480 | — | |
| Jan 3, 2018 AMForm 4 → | Jan 5, 8:09 pm EST | Robert E DavisSVP, Chief Scientific Officer | 116,292 | — | — | 48,480 | — | |
| Jan 3, 2018 AMForm 4 → | Jan 5, 8:06 pm EST | Lawrence J. HinelineVP of Finance CFO | 122,049 | — | — | 48,480 | — | |
| Jan 3, 2018 AMForm 4 → | Jan 5, 8:03 pm EST | Michael HalsteadSVP and General Counsel | 122,049 | — | — | 48,480 | — | |
| Dec 11, 2017 MForm 4 → | Dec 13, 4:52 pm EST | Richard A LernerDirector | 12,500 | — | — | 0 | — | |
| Dec 4, 2017 MForm 4 → | Dec 6, 6:33 pm EST | Robert E DavisSVP, Chief Scientific Officer | 1,757 | — | — | 1,758 | — | |
| Nov 13, 2017 AForm 4 → | Nov 15, 5:13 pm EST | Andrew SatlinEVP and Chief Medical Officer | 170,500 | — | — | 170,500 | — | |
| Oct 30, 2017 MForm 4 → | Nov 1, 8:04 pm EDT | Sharon MatesChairman, President & CEO, Director | 18,750 | — | — | 0 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 4:26 pm EDT | Robert L Van NostrandDirector | 20,000 | — | — | 20,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 4:24 pm EDT | Rory B RiggsDirector | 20,000 | — | — | 20,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 4:22 pm EDT | Joel S MarcusDirector | 20,000 | — | — | 20,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 4:20 pm EDT | Richard A LernerDirector | 20,000 | — | — | 20,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 4:18 pm EDT | Christopher D AlafiDirector, 10% Owner | 20,000 | — | — | 20,000 | — | |
| Jan 26, 2017 MForm 4 → | Jan 30, 6:13 pm EST | Joel S MarcusDirector | 95,000 | — | — | 0 | — | |
| Jan 3, 2017 AMForm 4 → | Jan 5, 6:00 pm EST | Kimberly E. VanoverSVP, Clinical Development | 41,357 | — | — | 3,108 | — | |
| Jan 3, 2017 AMForm 4 → | Jan 5, 5:58 pm EST | Sharon MatesChairman, President & CEO, Director | 175,775 | — | — | 13,208 | — | |
| Jan 3, 2017 AMForm 4 → | Jan 5, 5:56 pm EST | Lawrence J. HinelineVP of Finance CFO | 82,717 | — | — | 6,216 | — | |
| Jan 3, 2017 AMForm 4 → | Jan 5, 5:54 pm EST | Michael HalsteadSVP and General Counsel | 82,717 | — | — | 6,216 | — | |
| Dec 15, 2016 MForm 4 → | Dec 19, 5:50 pm EST | Kimberly E. VanoverSVP, Clinical Development | 18,750 | — | — | 0 | — | |
| Dec 4, 2016 AMForm 4 → | Jan 5, 2017, 5:47 pm EST | Robert E DavisSVP, Chief Scientific Officer | 41,561 | — | — | 7,946 | — | late |
| Jun 14, 2016 AForm 4 → | Jun 15, 4:27 pm EDT | Christopher D AlafiDirector, 10% Owner | 20,000 | — | — | 20,000 | — | |
| Jun 14, 2016 AForm 4 → | Jun 15, 4:26 pm EDT | Rory B RiggsDirector | 20,000 | — | — | 20,000 | — | |
| Jun 14, 2016 AForm 4 → | Jun 15, 4:24 pm EDT | Richard A LernerDirector | 20,000 | — | — | 20,000 | — | |
| Jun 14, 2016 AForm 4 → | Jun 15, 4:23 pm EDT | Joel S MarcusDirector | 20,000 | — | — | 20,000 | — | |
| Jun 14, 2016 AForm 4 → | Jun 15, 4:22 pm EDT | Robert L Van NostrandDirector | 20,000 | — | — | 20,000 | — | |
| Feb 18, 2016 MForm 4 → | Feb 19, 4:25 pm EST | Richard A LernerDirector | 10,000 | — | — | 0 | — | |
| Jan 4, 2016 AForm 4/A → | Apr 4, 5:05 pm EDT | Lawrence J. HinelineVP of Finance CFO | 48,630 | — | — | 9,323 | — | |
| Jan 4, 2016 AForm 4 → | Jan 6, 8:29 pm EST | Lawrence J. HinelineVP of Finance CFO | 48,630 | — | — | 9,323 | — | amended |
| Jan 4, 2016 AForm 4 → | Jan 6, 8:27 pm EST | Michael HalsteadSVP and General Counsel | 48,630 | — | — | 9,323 | — | |
| Jan 4, 2016 AForm 4 → | Jan 6, 8:25 pm EST | Sharon MatesChairman, President & CEO, Director | 103,339 | — | — | 19,811 | — | |
| Jan 4, 2016 AForm 4 → | Jan 6, 8:24 pm EST | Kimberly E. VanoverVP, Clinical Development | 24,314 | — | — | 4,661 | — | |
| Dec 22, 2015 GForm 4 → | Dec 23, 6:21 pm EST | Richard A LernerDirector | 290,000 | — | — | 20,000 | — | |
| Dec 11, 2015 MForm 4 → | Dec 15, 8:27 pm EST | Sharon MatesChairman, President & CEO, Director | 68,750 | — | — | 18,750 | — | |
| Dec 4, 2015 AForm 4 → | Dec 8, 5:33 pm EST | Robert E DavisSVP, Chief Scientific Officer | 27,502 | — | — | 5,272 | — | |
| Nov 24, 2015 MForm 4 → | Dec 15, 8:25 pm EST | Lawrence J. HinelineVP of Finance CFO | 47,500 | — | — | 0 | — | late |
| Sep 9, 2015 MForm 4 → | Sep 11, 4:53 pm EDT | Allen A. FienbergVP of Business Development | 12,500 | — | — | 0 | — | |
| Jun 16, 2015 AForm 4 → | Jun 22, 5:26 pm EDT | Robert L Van NostrandDirector | 20,000 | — | — | 20,000 | — | late |
| Jun 16, 2015 AForm 4 → | Jun 22, 5:24 pm EDT | Rory B RiggsDirector | 20,000 | — | — | 20,000 | — | late |
| Jun 16, 2015 AForm 4 → | Jun 22, 5:21 pm EDT | Joel S MarcusDirector | 20,000 | — | — | 20,000 | — | late |
| Jun 16, 2015 AForm 4 → | Jun 22, 5:20 pm EDT | Richard A LernerDirector | 20,000 | — | — | 20,000 | — | late |
| Jun 16, 2015 AForm 4 → | Jun 22, 5:19 pm EDT | Christopher D AlafiDirector, 10% Owner | 20,000 | — | — | 20,000 | — | late |
| May 19, 2015 MForm 4 → | May 20, 5:19 pm EDT | Lawrence P. WennogleVice President, Drug Discovery | 47,500 | — | — | 0 | — | |
| Mar 31, 2015 MForm 4 → | Apr 2, 4:59 pm EDT | Allen A. FienbergVP of Business Development | 12,500 | — | — | 0 | — | |
| Mar 31, 2015 MForm 4 → | Apr 2, 4:58 pm EDT | Joel S MarcusDirector | 15,000 | — | — | 0 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:19 pm EST | Juan F. SanchezVP, Corp. Communications & IR | 30,050 | — | — | 30,050 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:19 pm EST | Lawrence P. WennogleVice President, Drug Discovery | 12,020 | — | — | 12,020 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:18 pm EST | Allen A. FienbergVP of Business Development | 40,066 | — | — | 40,066 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:18 pm EST | Kimberly E. VanoverVP, Clinical Development | 72,120 | — | — | 72,120 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:17 pm EST | Lawrence J. HinelineVP of Finance CFO | 72,120 | — | — | 72,120 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:17 pm EST | Michael HalsteadSVP and General Counsel | 88,146 | — | — | 88,146 | — | |
| Jan 2, 2015 AForm 4 → | Jan 6, 5:16 pm EST | Sharon MatesChairman, President & CEO, Director | 228,380 | — | — | 228,380 | — |